Document:

Kindred Healthcare, Inc. 2001 Stock Incentive Plan, Amended and Restated

 Exhibit 10.1 
 KINDRED HEALTHCARE, INC. 2001 STOCK INCENTIVE PLAN 
 Amended and Restated 
 1. Purpose of the Plan 
 This Amended and Restated
Kindred Healthcare, Inc. 2001 Stock Incentive Plan (the “Plan”), originally adopted as the Kindred Healthcare, Inc. 2001 Stock Option Plan, is intended to promote the interests of the Company by providing the employees of the Company, who
are largely responsible for the management, growth and protection of the business of the Company, with incentives and rewards to encourage them to continue in the employ of the Company. 
 2. Definitions 
 As used in the Plan, the following definitions apply to the terms indicated below:

 (a) “Affiliates” shall mean with respect to any person, any other person that, directly or indirectly through one or more
intermediaries, controls, is controlled by, or is under common control with the first person. 
 (b) “Board of Directors” shall
mean the Board of Directors of Kindred. 
 (c) “Cause,” when used in connection with the termination of a Participant’s
employment, shall mean (i) dishonesty; (ii) deliberate and continual refusal to perform employment duties on substantially a full-time basis; (iii) failure to act in accordance with any specific lawful instructions given to the
Participant in connection with the performance of his duties for the Company, unless the Participant has an existing Disability; (iv) deliberate misconduct that is reasonably likely to be materially damaging to the Company without a reasonable
good faith belief by the Participant that such conduct was in the best interests of the Company; or (v) conviction of or plea of nolo contendere to a crime involving moral turpitude. 
 (d) “Change in Control” shall mean any one of the following events: 
 (i) any Person (as this term is used in Sections 3(a)(9) and 13(d)(3) of the Exchange Act, but excluding any person described in and
satisfying the conditions of Rule 13d-1(b)(1)(i) thereunder) (an “Acquiring Person”) becomes the “beneficial owner” (as such term is defined in Rule 13d-3 promulgated under the Exchange Act (a “Beneficial
Owner”), directly or indirectly, of securities of the Company representing 50% or more of the combined voting power of the Company’s then outstanding securities, other than beneficial ownership by a Participant, the Company, any employee
benefit plan of the Company or any Person organized, appointed or established pursuant to the terms of any such benefit plan; 
 (ii) The Company’s stockholders approve an agreement to merge or consolidate the Company with another corporation, or an agreement providing for the sale of substantially all of the assets of the Company to one or more Persons, in any
case other than with or to an entity 50% or more of which is controlled by, or is under common control with, the Company; 
 (iii) during any two-year period, individuals who at the date on which the period commences constitute a majority of the Board of Directors (the “Incumbent Directors”) cease to constitute a majority thereof for any reason;
provided, however, that a director who was not an Incumbent Director shall be deemed to be an Incumbent Director if such director was elected by, or on the recommendation of, at least two-thirds of the Incumbent Directors (either
actually or by prior operation of this provision), other than any director who is so approved in connection with any actual or threatened contest for election to positions on the Board of Directors; or 
  

 1 

 (iv) the Company is merged, combined, consolidated, recapitalized or otherwise organized
with one or more other entities that are not affiliates of the Company, as a result of which less than 50% of the outstanding voting securities of the surviving or resulting entity immediately after such event are, or will be, owned, directly or
indirectly, by shareholders of the Company, determined on the basis of record ownership as of the date of determination of holders entitled to vote on the transaction (or in the absence of a vote, the day immediately prior to the event). 

Notwithstanding the foregoing, a Change in Control shall not be deemed to occur as a result of any event or transaction to the extent
that treating such event or transaction as a Change in Control would cause any tax to become due under Section 409A of the Code. 
 (e)
“Code” shall mean the Internal Revenue Code of 1986, as amended from time to time. 
 (f) “Committee” shall have the
meaning given to such term in Section 4. 
 (g) “Common Stock” shall mean the Company’s common stock, $.25 par value per
share. 
 (h) “Company” shall mean Kindred together with its Affiliates. 
 (i) “Disability” shall mean a physical or mental condition that entitles the Participant to benefits under the Company’s long-term
disability plan. For purposes of this Plan, a Participant’s employment shall be deemed to have terminated as a result of Disability on the date as of which he is first entitled to receive disability benefits under such policy. 
 (j) “EBITDAR” shall mean the consolidated earnings of Kindred and its subsidiaries before interest, taxes, depreciation, amortization and rent.

 (k) “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended. 
 (l) the “Fair Market Value” of a Share with respect to any day shall be (i) the closing sales price on such day of a Share as reported on
the principal securities exchange on which Shares are then listed or admitted to trading or (ii) if not so reported, the average of the closing bid and ask prices on such day as reported on the National Association of Securities Dealers
Automated Quotation System or (iii) if not so reported, as furnished by any member of the National Association of Securities Dealers, Inc. selected by the Committee. In the event that the price of a Share shall not be so reported, the Fair
Market Value of a Share shall be determined by the Committee in its absolute discretion. 
 (m) “Incentive Award” shall mean an
Option, Tandem SAR, Stand-Alone SAR, Performance Unit, Restricted Share or Stock Bonus granted pursuant to the terms of the Plan. 
 (n)
“Incentive Stock Option” shall mean an Option which is an “incentive stock option” within the meaning of Section 422 of the Code and which is identified as an Incentive Stock Option in the agreement by which it is evidenced.

 (o) “Kindred” shall mean Kindred Healthcare, Inc., a Delaware corporation, and its successors. 
 (p) “Non-Qualified Stock Option” shall mean an Option which is not an Incentive Stock Option and which is identified as a Non-Qualified Stock
Option in the agreement by which it is evidenced. 
 (q) “Option” shall mean an option to purchase Shares granted pursuant to
Section 6 hereof. Each Option shall be identified as either an Incentive Stock Option or a Non-Qualified Stock Option in the agreement by which it is evidenced. 
  

 2 

 (r) “Participant” shall mean an employee of the Company to whom an Incentive Award is granted
pursuant to the Plan, and upon his death, his successors, heirs, executors and administrators, as the case may be. 
 (s) “Performance
Goals” shall have the meaning given such term in Section 9(b). 
 (t) “Performance Period” shall have the meaning given
such term in Section 9(a). 
 (u) “Performance Unit” shall mean the right, granted to a Participant pursuant to
Section 9, to receive a Share upon the achievement of specified Performance Goals. 
 (v) “Person” shall mean a
“person,” as such term is used in Sections 13(d) and 14(d) of the Exchange Act. 
 (w) “Plan” shall mean this
Kindred Healthcare, Inc. 2001 Stock Incentive Plan, as it may be amended from time to time. 
 (x) “Restricted Share” shall mean a
Share of restricted stock granted pursuant to Section 10 hereof. 
 (y) “Retirement” shall mean the termination of the
employment of a Participant with the Company on or after (i) the first date on which the Participant has both attained age 55 and completed 5 years of service with the Company or (ii) the date on which the Participant attains age 65.

 (z) “Securities Act” shall mean the Securities Act of 1933, as amended. 
 (aa) “Share” shall mean a share of Common Stock. 
 (bb) “Spread” shall mean, with respect to an Option, Tandem SAR or Stand-Alone SAR, the excess, if any, of (i) the Fair Market Value of a Share as of the applicable valuation date (e.g., the date such
Incentive Award is exercised) over (ii) in the case of an Option, the exercise price of such Option, or in the case of a Tandem SAR, the exercise price of the related Option, or in the case of a Stand-Alone SAR, the exercise price of such
Stand-Alone SAR. 
 (cc) “Stand-Alone SAR” shall mean a stock appreciation right granted pursuant to Section 8 hereof which is
not related to any Option. 
 (dd) “Stock Bonus” shall mean a grant of a bonus payable in Shares pursuant to Section 11
hereof. 
 (ee) “Tandem SAR” shall mean a stock appreciation right granted pursuant to Section 7 hereof which is related to an
Option. Each Tandem SAR shall be exercisable only to the extent its related Option is exercisable and only in the alternative to the exercise of its related Option. 
 3. Stock Subject to the Plan 
 Under the Plan, the Committee may grant to Participants
(i) Options, (ii) Tandem SARs, (iii) Stand-Alone SARs, (iv) Performance Units, (v) Restricted Shares and (vi) Stock Bonuses. 
 Subject to adjustment as provided in Section 12 hereof, the Committee may grant Incentive Awards with respect to a number of Shares that in the aggregate does not exceed 9,269,291 Shares; provided that
(i) no Participant may be granted (a) Options with respect to more than 150,000 Shares in the aggregate in any calendar year; (b) Tandem SARs or Stand-Alone SARs (collectively) with respect to more than 100,000 Shares in the aggregate
in any calendar year; (c) Performance Units with respect to more than 100,000 Shares in the aggregate in any calendar year; (d) Restricted Shares with respect to more than 100,000 Shares in the aggregate in any calendar year; or
(e) Stock Bonuses with respect to more than 25,000 Shares in the aggregate in any calendar year and (ii)

  

 3 

 
shares issued during the term of the Plan for Incentive Awards other than Options, Stand-Alone SARS and Tandem SARS shall in no event exceed fifty percent
(50%) of the shares authorized under the Plan. 
 In the event that any outstanding Option, Stand-Alone SAR, Restricted Share or
Performance Unit expires, terminates or is cancelled for any reason (other than pursuant to Section 7(b)(ii) hereof), the Shares subject to the unexercised portion of such Option, Stand-Alone SAR, Restricted Share or Performance Unit shall
again be available for grants under the Plan. In the event that an outstanding Option is cancelled pursuant to Section 7(b)(ii) hereof by reason of the exercise of a Tandem SAR, the Shares subject to the cancelled portion of such Option shall
not again be available for grant under the Plan. To the extent that Incentive Awards terminate, expire or are cancelled without having been exercised, vested or paid, the Shares covered thereby shall continue to count against the annual maximum
number of Shares with respect to which each type of Incentive Award may be granted to a Participant. 
 Shares issued under the Plan may be
either newly issued shares or treasury shares, at the discretion of the Committee. 
 4. Administration of the Plan 
 The Plan shall be administered by a committee of the Board (the “Committee”) consisting of two or more persons, each of whom shall be a
(i) “non-employee director” within the meaning of Rule 16b-3 promulgated under Section 16 of the Exchange Act (ii) an “outside director” within the meaning of Treasury Regulation section 1.162-27(e)(3)
promulgated under Section 162(m) of the Code and (iii) an “independent” director as required by NYSE or any security exchange on which the Common Stock is listed. The Committee shall from time to time designate the employees of
the Company who shall be granted Incentive Awards. 
 The Committee shall have full authority to administer the Plan, including authority to
interpret and construe any provision of the Plan and the terms of any Incentive Award issued under it and to adopt such rules and regulations for administering the Plan as it may deem necessary. Decisions of the Committee shall be final and binding
on all parties. 
 The Committee may, in its absolute discretion, accelerate the date on which any Option or Stand-Alone SAR granted under
the Plan becomes exercisable or on which a Restricted Share granted under the plan vests or, subject to Sections 6(c)(i) and 8(c)(i) hereof, extend the term of any Option or Stand-Alone SAR granted under the Plan. In addition, the Committee may
modify, with the consent of the Participant, any Incentive Award to make it consistent with other agreements approved by the Committee. 
 Whether an authorized leave of absence, or absence in military or government service, shall constitute termination of employment shall be determined by the Committee; provided that, no payment shall be made with respect to any Incentive
Award that is subject to Section 409A of the Code as a result of any such authorized leave of absence or absence in military or government service unless such authorized leave or absence constitutes a separation from service for purposes of
Section 409A of the Code and the regulations promulgated thereunder. 
 Neither the Committee nor any member of the Committee shall be
liable for any action, omission, or determination relating to the Plan, and the Company shall indemnify and hold harmless each member of the Committee and each other director or employee of the Company to whom any duty or power relating to the
administration or interpretation of the Plan has been delegated against any cost or expense (including counsel fees) or liability (including any sum paid in settlement of a claim with the approval of the Committee) arising out of any action,
omission or determination relating to the Plan, unless, in either case, such action, omission or determination was taken or made by such member, director or employee in bad faith and without reasonable belief that it was in the best interests of the
Company. 
  

 4 

 5. Eligibility 
 The persons who shall be eligible to receive Incentive Awards pursuant to the Plan shall be such employees of the Company who are largely responsible for the management, growth and protection of the business of the
Company (including officers of the Company, whether or not they are directors of the Company) as the Committee shall select from time to time. 
 6.
Options 
 The Committee may grant Options pursuant to the Plan which Options shall be evidenced by agreements in such form as the
Committee shall from time to time approve. Options shall comply with and be subject to the following terms and conditions: 
 (a)
Identification of Options 
 All Options granted under the Plan shall be clearly identified in the agreement evidencing such Options as
either Incentive Stock Options or Non-Qualified Stock Options. 
 (b) Exercise Price 
 The exercise price of any Option granted under the Plan shall be not less than 100% of the Fair Market Value of a Share on the date on which such Option
is granted. 
 (c) Term and Exercise of Options 
 (i) Each Option shall be exercisable on such date or dates, during such period and for such number of Shares as shall be determined by
the Committee on the day on which such Option is granted and set forth in the agreement evidencing such Option; provided, however, that no Option shall be exercisable after the expiration of ten years from the date such Option was
granted; and, provided, further, that each Option shall be subject to earlier termination, expiration or cancellation as provided in the Plan or in the agreement evidencing such Option. 
 (ii) Each Option shall be exercisable in whole or in part. The partial exercise of an Option shall not cause the expiration, termination
or cancellation of the remaining portion thereof. 
 (iii) An Option shall be exercised by delivering notice to the
Company’s principal office, to the attention of its Corporate Secretary, no less than three business days in advance of the effective date of the proposed exercise. Such notice shall specify the number of Shares with respect to which the Option
is being exercised and the effective date of the proposed exercise and shall be signed by the Participant. The Participant may withdraw such notice at any time prior to the close of business on the business day immediately preceding the effective
date of the proposed exercise. Payment for Shares purchased upon the exercise of an Option shall be made on the effective date of such exercise either (i) in cash, by certified check, bank cashier’s check or wire transfer or (ii) in
Shares previously owned by the Participant for at least six months and valued at their Fair Market Value on the effective date of such exercise, or partly in Shares with the balance in cash, by certified check, bank cashier’s check or wire
transfer. In addition, Options may be exercised through a registered broker-dealer pursuant to such cashless exercise procedures which are, from time to time, deemed acceptable by the Company. Any payment in Shares shall be effected by the delivery
of such Shares to the Corporate Secretary of the Company, duly endorsed in blank or accompanied by stock powers duly executed in blank, together with any other documents and evidences as the Corporate Secretary of the Company shall require from time
to time. 
 (iv) Certificates for Shares purchased upon the exercise of an Option shall be issued in the name of the
Participant and delivered to the Participant as soon as practicable following the effective date on which the Option is exercised. 
  

 5 

 (v) During the lifetime of a Participant, each Option granted to him shall be exercisable
only by him. No Option shall be assignable or transferable otherwise than by will or by the laws of descent and distribution. 
 (d)
Limitations on Grant of Incentive Stock Options 
 (i) The aggregate Fair Market Value of Shares with respect to which
“incentive stock options” (within the meaning of Section 422 of the Code) are exercisable for the first time by a Participant during any calendar year under the Plan and any other stock option plan of the Company (or any
“subsidiary” of the Company as such term is defined in Section 424(f) of the Code) shall not exceed $100,000. Such Fair Market Value shall be determined as of the date on which each such incentive stock option is granted. In the event
that the aggregate Fair Market Value of Shares with respect to such incentive stock options exceeds $100,000, then Incentive Stock Options granted hereunder to such Participant shall, to the extent and in the order required by regulations
promulgated under the Code (or any other authority having the force of regulations), automatically be deemed to be Non-Qualified Stock Options, but all other terms and provisions of such Incentive Stock Options shall remain unchanged. In the absence
of such regulations (and authority), or in the event such regulations (or authority) require or permit a designation of the options which shall cease to constitute incentive stock options, Incentive Stock Options shall, to the extent of such excess
and in the order in which they were granted, automatically be deemed to be Non-Qualified Stock Options, but all other terms and provisions of such Incentive Stock Options shall remain unchanged. 
 (ii) No Incentive Stock Option may be granted to an individual if, at the time of the proposed grant, such individual owns stock
possessing more than ten percent of the total combined voting power of all classes of stock of Kindred or any of its “subsidiaries” (within the meaning of Section 424(f) of the Code), unless (i) the exercise price per Share of
such Incentive Stock Option is at least one hundred and ten percent of the Fair Market Value of a Share at the time such Incentive Stock Option is granted and (ii) such Incentive Stock Option is not exercisable after the expiration of five
years from the date such Incentive Stock Option is granted. 
 (e) Effect of Termination of Employment 
 (i) In the event that the employment of a Participant with the Company shall terminate for any reason other than Disability, Retirement,
Cause or death (A) Options granted to such Participant, to the extent that they were exercisable at the time of such termination, shall remain exercisable for 90 days after such termination, at which time they shall expire, and (B) Options
granted to such Participant, to the extent that they were not exercisable at the time of such termination, shall expire at the commencement of business on the date of such termination; provided, however, that no Option shall be
exercisable after the expiration of its term. 
 (ii) In the event that the employment of a Participant with the Company
shall terminate on account of the Retirement of the Participant, (A) such Participant shall be entitled to exercise Options granted to him hereunder to the extent that such Options were exercisable at the time of such termination (x) in
the case of Non-Qualified Stock Options, for two years after the date of Retirement and (y) in the case of Incentive Stock Options, for 90 days after Retirement, and (B) Options granted to such Participant, to the extent that they were not
exercisable at the time of such termination, shall expire at the commencement of business on the date of such termination; provided, however, that no Option shall be exercisable after the expiration of its term. 
 (iii) In the event that the employment of a Participant with the Company shall terminate on account of the Disability or death of the
Participant, all then outstanding Options of such Participant shall become immediately exercisable and such Participant shall be entitled to exercise Options granted to him hereunder (x) in the case of Non-Qualified Stock Options, at any time
within two years after the date of death or the determination of Disability, and (y) in the case of Incentive Stock Options, at any time within 

  

 6 

 
one year after the date of death or determination of Disability; provided, however, that no Option shall be exercisable after the expiration of
its term. 
 (iv) In the event of the termination of a Participant’s employment for Cause, all outstanding Options
granted to such Participant shall expire at the commencement of business on the date of such termination. 
 (f) Consequences of a Change in
Control 
 Upon the occurrence of a Change in Control, each Option granted under the Plan and outstanding at such time shall become fully and
immediately exercisable and shall remain exercisable until its expiration, termination or cancellation pursuant to the terms of the Plan. Furthermore, the Committee may specify in the agreement evidencing an Option that the Participant receiving
such Option shall, following a Change in Control, have the right to sell the Option back to the Company for an amount equal to the Spread. 
 7. Tandem
Stock Appreciation Rights 
 The Committee may grant in connection with any Option granted hereunder one or more Tandem SARs relating to
a number of Shares less than or equal to the number of Shares subject to the related Option. A Tandem SAR may be granted at the same time as, or subsequent to the time that, its related Option is granted. Each Tandem SAR shall be evidenced by an
agreement in such form as the Committee shall from time to time approve. Tandem SARs shall comply with and be subject to the following terms and conditions: 
 (a) Benefit Upon Exercise 
 Subject to Section 7(c) hereof, the exercise of a Tandem SAR with respect
to any number of Shares prior to the occurrence of a Change in Control shall entitle a Participant to (i) a cash payment, for each such Share, equal to the Spread, (ii) the issuance or transfer to the Participant of a number of Shares
which on the date of the exercise of the Tandem SAR have a Fair Market Value equal to such Spread or (iii) a combination of cash and Shares in amounts equal to such Spread, all as determined by the Committee in its discretion. Such payment,
transfer or issuance shall occur as soon as practical, but in no event later than the expiration of five business days, after the effective date of such exercise. 
 (b) Term and Exercise of Tandem SAR 
 (i) A Tandem SAR shall be exercisable at the same time
and to the same extent (on a proportional basis, with any fractional amount being rounded down to the immediately preceding whole number) as its related Option. 
 (ii) The exercise of a Tandem SAR with respect to a number of Shares shall cause the immediate and automatic cancellation of its related
Option with respect to an equal number of Shares. The exercise of an Option, or the cancellation, termination or expiration of an Option (other than pursuant to this subsection (ii)), with respect to a number of Shares shall cause the automatic
and immediate cancellation of its related Tandem SARs to the extent that the number of Shares subject to such Option after such exercise, cancellation, termination or expiration is less than the number of Shares subject to such Tandem SARs. Such
Tandem SARs shall be cancelled in the order in which they became exercisable. 
 (iii) Each Tandem SAR shall be exercisable
in whole or in part; provided, that no partial exercise of a Tandem SAR shall be for an aggregate exercise price of less than $1,000. The partial exercise of a Tandem SAR shall not cause the expiration, termination or cancellation of the
remaining portion thereof. 
  

 7 

 (iv) During the lifetime of a Participant, each Tandem SAR granted to him shall be
exercisable only by him. No Tandem SAR shall be assignable or transferable otherwise than by will or by the laws of descent and distribution and otherwise than together with its related Option. 
 (v) A Tandem SAR shall be exercised by delivering notice to the Company’s principal office, to the attention of its Corporate
Secretary, no less than three business days in advance of the effective date of the proposed exercise. Such notice shall specify the number of Shares with respect to which the Tandem SAR is being exercised and the effective date of the proposed
exercise and shall be signed by the Participant. The Participant may withdraw such notice at any time prior to the close of business on the business day immediately preceding the effective date of the proposed exercise. 
 (c) Consequences of a Change in Control 
 The exercise of a Tandem SAR with respect to any number of Shares upon or after the occurrence of a Change in Control shall entitle a Participant to a cash payment, for each such Share, equal to the Spread. 
 8. Stand-Alone Stock Appreciation Rights 
 The
Committee may grant Stand-Alone SARs pursuant to the Plan, which Stand-Alone SARs shall be evidenced by agreements in such form as the Committee shall from time to time approve. Stand-Alone SARs shall comply with and be subject to the following
terms and conditions: 
 (a) Exercise Price 
 The exercise price of any Stand-Alone SAR granted under the Plan shall be determined by the Committee at the time of the grant of such Stand-Alone SAR but shall not be less than 100% of the Fair Market Value of a
Share on the date on which such Stand-Alone SAR is granted. 
 (b) Benefit Upon Exercise 
 Subject to Section 8(e) hereof, the exercise of a Stand-Alone SAR with respect to any number of Shares prior to the occurrence of a Change in
Control shall entitle a Participant to (i) a cash payment, for each such Share, equal to the Spread, (ii) the issuance or transfer to the Participant of a number of Shares which on the date of the exercise of the Stand-Alone SAR have a
Fair Market Value equal to such Spread or (iii) a combination of cash and Shares in amounts equal to such Spread, all as determined by the Committee in its absolute discretion. Such payment, transfer or issuance shall occur as soon as
practical, but in no event later than five business days, after the effective date of the exercise. 
 (c) Term and Exercise of Stand-Alone
SARs 
 (i) Each Stand-Alone SAR shall be exercisable on such date or dates, during such period and for such number of Shares
as shall be determined by the Committee and set forth in the agreement with respect to such Stand-Alone SAR; provided, however, that no Stand-Alone SAR shall be exercisable after the expiration of ten years from the date such
Stand-Alone SAR was granted; and, provided, further, that each Stand-Alone SAR shall be subject to earlier termination, expiration or cancellation as provided in the Plan or in the agreement evidencing such Stand-Alone SAR. 

(ii) Each Stand-Alone SAR may be exercised in whole or in part; provided, that no partial exercise of a Stand-Alone SAR shall
be for an aggregate exercise price of less than $1,000. The partial exercise of a Stand-Alone SAR shall not cause the expiration, termination or cancellation of the remaining portion thereof. 
 (iii) A Stand-Alone SAR shall be exercised by delivering notice to the Company’s principal office, to the attention of its Corporate
Secretary, no less than three business days in advance of the 

  

 8 

 
effective date of the proposed exercise. Such notice shall specify the number of Shares with respect to which the Stand-Alone SAR is being exercised and the
effective date of the proposed exercise and shall be signed by the Participant. The Participant may withdraw such notice at any time prior to the close of business on the business day immediately preceding the effective date of the proposed
exercise. 
 (iv) During the lifetime of a Participant, each Stand-Alone SAR granted to him shall be exercisable only by him.
No Stand-Alone SAR shall be assignable or transferable otherwise than by will or by the laws of descent and distribution. 
 (d) Effect of
Termination of Employment 
 (i) In the event that the employment of a Participant with the Company shall terminate for any
reason other than Disability, Retirement, Cause or death (A) Stand-Alone SARs granted to such Participant, to the extent that they were exercisable at the time of such termination, shall remain exercisable for 90 days after such termination, at
which time they shall expire, and (B) Stand-Alone SARs granted to such Participant, to the extent that they were not exercisable at the time of such termination, shall expire at the commencement of business on the date of such termination;
provided, however, that no Stand-Alone SAR shall be exercisable after the expiration of its term. 
 (ii) In
the event that the employment of a Participant with the Company terminates on account of the Retirement of the Participant, (A) such Participant shall be entitled to exercise Stand-Alone SARs granted to him hereunder, to the extent that such
Stand-Alone SARs were exercisable at the time of such termination, for two years after the date of Retirement, and (B) Stand-Alone SARs granted to such Participant, to the extent that they were not exercisable at the time of such termination,
shall expire at the commencement of business on the date of such termination; provided, however, that no Stand-Alone SAR shall be exercisable after the expiration of its term. 
 (iii) In the event that the employment of a Participant with the Company shall terminate on account of the Disability or death of the
Participant (x) Stand-Alone SARs granted to such Participant, to the extent that they were exercisable at the time of such termination, shall remain exercisable until the expiration of two years after such termination, on which date they shall
expire, and (y) Stand-Alone SARs granted to such Participant, to the extent that they were not exercisable at the time of such termination, shall expire at the close of business on the date of such termination; provided, however,
that no Stand-Alone SAR shall be exercisable after the expiration of its term. 
 (iv) In the event of the termination of a
Participant’s employment for Cause, all outstanding Stand-Alone SARs granted to such Participant shall expire at the commencement of business on the date of such termination. 
 (e) Consequences of a Change in Control 
 Upon the occurrence of a Change in Control, any Stand-Alone SAR granted under the Plan and outstanding at such time shall become fully and immediately exercisable and shall remain exercisable until its expiration, termination or
cancellation pursuant to the terms of the Plan. The exercise of a Stand-Alone SAR with respect to any number of Shares upon or after the occurrence of a Change in Control shall entitle a Participant to a cash payment, for each such Share, equal to
the Spread. 
 9. Performance Units 
 The
Committee may grant Performance Units pursuant to the Plan, which Performance Units shall be evidenced by agreements in such form as the Committee shall from time to time approve. Performance Units shall be based upon the achievement of Performance
Goals over a specified Performance Period and shall comply with and be subject to the following terms and conditions: 
  

 9 

 (a) Performance Period 
 The Committee shall determine the period of performance (“Performance Period”), with respect to each Performance Unit, during which the Performance Goals will be measured. The Performance Period shall not be
less than six months nor more than five years. 
 (b) Performance Goals 
 The goals (“Performance Goals”) that are to be achieved with respect to each Performance Unit shall be those objectives established by the
Committee as it deems appropriate, and which may be expressed in terms of (i) earnings per Share, (ii) Share price, (iii) pre-tax profit, (iv) net income, (v) return on equity or assets, (vi) revenues,
(vii) account receivable collection days, (viii) EBITDAR, (ix) individual management, performance or quality objectives, (x) any combination of the foregoing, or (xi) such other goals as the Committee may determine (except
with respect to executive officers). Performance Goals may be in respect of the performance of Kindred and its subsidiaries (which may be on a consolidated basis) or a subsidiary, division or other operating unit of the Company. Performance Goals
may be absolute or relative and may be expressed in terms of a progression within a specified range. The Committee shall establish Performance Goals applicable to a particular Performance Period within 90 days of the commencement of such Performance
Period (or, in the case of a Performance Period that is less than 12 months in duration, before 25% of such Performance Period has elapsed), provided that the outcome of the Performance Goal is substantially uncertain at the time of its adoption.
The Performance Goals with respect to a Performance Period shall be established by the Committee in order to comply with Section 162(m) of the Code, as applicable. The Committee shall determine the target levels of performance that must be
achieved with respect to each criteria that is identified in a Performance Goal in order for a Performance Goal to be treated as attained in whole or in part; provided that the Committee shall establish each such target level of performance so that
any vesting condition related to the attainment of the Performance Goals would be considered a substantial risk of forfeiture for purposes of Section 409A of the Code and the regulations promulgated thereunder. In the event that the Performance
Goals are based on more than one business criteria, the Committee may determine to make a grant of a Performance Unit upon attainment of the Performance Goal relating to any one or more of such criteria. 
 (c) Benefit Upon Achievement of Performance Goals 
 As soon as practicable after the end of a Performance Period, the Committee shall determine and
certify the extent to which the Performance Goals for such Performance Period were achieved, if at all. If the Performance Goals are achieved in full, and the Participant remains employed with the Company as of the end of the relevant Performance
Period, the Participant will be allocated Shares equal to the number of Performance Units initially awarded to the Participant for the relevant Performance Period. Each award of Performance Units may provide for the allocation of fewer Performance
Units in the event of partial fulfillment of Performance Goals. After certifying the extent of any Performance Goals, the Committee may determine at the time of payment whether such payment shall be made (a) in cash (equal to the Fair Market
Value of a Share multiplied by the number of Performance Units being allocated), (b) in Shares or (c) in a combination of cash and Shares. Notwithstanding the foregoing, in no event shall any payment pursuant to this Section 9(c)
occur later than March 15th of the calendar year immediately following the calendar year in which the relevant Performance Period ends.

 (d) No Transferability 
 No
Performance Unit shall be assignable or transferable otherwise than by will or the laws of descent and distribution. 
 (e) Effect of
Termination of Employment 
 (i) If the employment of a Participant shall terminate with the Company prior to the expiration
of a Performance Period for any reason other than for death or Disability, the Performance Units then held by the Participant shall terminate. 
  

 10 

 (ii) In the event that the employment of a Participant with the Company shall terminate
on account of the Disability or death of the Participant prior to the expiration of a Performance Period with respect to which such Participant has Performance Units outstanding, all such outstanding Performance Units shall be paid to the
Participant or the Participant’s estate, as the case may be, as if all applicable Performance Goals had been fully achieved; provided that such payment shall be prorated to reflect the portion of the Performance Period during which such
Participant was employed. 
 (f) Consequences Upon Change in Control 
 Upon a Change in Control, any and all outstanding Performance Units which are potentially available under any outstanding award shall become fully
vested and immediately payable as if the Performance Goals were fully achieved, without any proration, in which case payment shall be in cash equal to the product of the number of outstanding Performance Units and the greater of (i) the Fair
Market Value of a Share on the date of such Change in Control and (ii) the highest price per Share paid in connection with such Change in Control. 
 10. Restricted Shares 
 The Committee may grant Restricted Shares pursuant to the Plan, which Restricted Shares shall be
evidenced by agreements in such form as the Committee shall from time to time approve. Restricted Shares shall comply with and be subject to the following terms and conditions: 
 (a) Vesting 
 Subject to the provisions of
Section 10(b) hereof, the Restricted Shares granted to a Participant shall not be transferred, pledged, assigned or otherwise encumbered and shall be subject to forfeiture until such Restricted Shares vest and become fully transferable without
restriction according to the vesting schedule set forth in the agreement evidencing such Restricted Shares. Any Restricted Shares shall vest over a period of at least three years from the date of grant. 
 (b) Effect of Termination of Employment 
 (i) If employment of a Participant with the Company shall terminate prior to the scheduled vesting dates of any Restricted Shares for any reason other than death or Disability, all Restricted Shares awarded to such
Participant that have not vested shall be forfeited on the date of such termination without payment of any consideration therefor. 
 (ii) In the event that the employment of a Participant with the Company shall terminate on account of the Disability or death of the Participant prior to the expiration of any vesting period, all Restricted Shares awarded to such
Participant shall immediately vest. 
 (c) Consequences of a Change in Control 
 Upon a Change in Control, any Restricted Share granted under the Plan and outstanding at such time shall vest and become fully transferable. 

11. Stock Bonuses 
 The Committee may grant Stock
Bonuses in such amounts as it shall determine from time to time. A Stock Bonus shall be paid at such time and subject to such conditions as the Committee shall determine at the time of the grant of such Stock Bonus; provided that to the extent that
any such Stock Bonus may be subject to Section 409A of the Code, the agreement evidencing the grant of such Stock Bonus shall contain terms and conditions (including, without limitation, deferral and payment provisions), that comply with
Section 409A of the Code and the regulations promulgated thereunder. Certificates for Shares granted as a Stock Bonus shall be issued in the name of the 

  

 11 

 
Participant to whom such grant was made and delivered to such Participant as soon as practicable after the date on which such Stock Bonus is required to be
paid. 
 12. Adjustment Upon Changes in Common Stock 
 (a) Shares Available for Grants 
 In the event of any change in the number of Shares outstanding by reason
of any stock dividend or split, recapitalization, merger, consolidation, combination or exchange of shares or similar corporate change, the maximum number and classes of Shares and limits on Incentive Awards with respect to which the Committee may
grant Incentive Awards shall be appropriately adjusted by the Committee. In the event of any change in the number of Shares outstanding by reason of any other event or transaction, the Committee shall make equitable adjustments in the number and
class of Shares with respect to which Incentive Awards may be granted. 
 (b) Adjustments to Outstanding Incentive Awards 
 (i) In the event of any change in the capitalization of the Company or other corporate change or transaction involving the Company or its
securities, the Committee shall make equitable adjustments in the number and class of shares subject to Options (including any Tandem SARs related thereto), Stand-Alone SARs, Restricted Shares and Performance Units outstanding on the date on which
such change occurs and in the exercise price of any such Option, Tandem SAR or Stand-Alone SAR. In the event of the occurrence of any transaction or event that has a substantial impact on the achievement of Performance Goals, the Committee shall
make equitable adjustments to any such Performance Goals with respect to any then-current Performance Period. 
 (ii) In the
event of (w) a dissolution or liquidation of the Company, (x) a sale of all or substantially all of the Company’s assets, (y) a merger or consolidation involving the Company in which the Company is not the surviving corporation
or (z) a merger or consolidation involving the Company in which the Company is the surviving corporation but the holders of Shares receive securities of another corporation and/or other property, including cash, the Committee shall, subject to
Section 409A of the Code to the extent applicable, either: 
 (A) cancel each Option (including each Tandem SAR related
thereto), Stand-Alone SAR, Performance Unit and Restricted Share outstanding immediately prior to such event (whether or not then exercisable), and, in full consideration of such cancellation, pay to the Participant to whom such Option, Stand-Alone
SAR, Performance Unit or Restricted Share was granted an amount in cash equal to (x) for each Share subject to an Option or Stand-Alone SAR, respectively, the excess of (A) the value of the property (including cash) received by the
holder of a Share as a result of such event over (B) the exercise price of such Option or Stand-Alone SAR, or (y) for each Restricted Share or Performance Unit, the value of the property (including cash) received by the holder of a Share;
or 
 (B) provide for the exchange of each Option (including any related Tandem SAR), Stand-Alone SAR, Performance Unit and
Restricted Share outstanding immediately prior to such event (whether or not then vested or exercisable) for an option, a stock appreciation right or a share of restricted stock with respect to, as appropriate, some or all of the property which a
holder of the number of Shares subject to such Option, Stand-Alone SAR, Performance Unit or Restricted Share would have received in such transaction and, incident thereto, make an equitable adjustment, in accordance with U.S. Department of Treasury
Regulation §1.409A-1(b)(5)(v)(D), in the exercise price of the option or stock appreciation right, and/or the number of shares or amount of property subject to the option, stock appreciation right or share of restricted stock, or, if
appropriate, provide for a cash payment to the Participant to whom such Option, Stand-Alone SAR, Performance Unit or Restricted Share was granted in partial consideration for the exchange of the Option, Stand-Alone SAR, Performance Unit or
Restricted Share. 
  

 12 

 (c) No Other Rights 
 Except as expressly provided in the Plan, no Participant shall have any rights by reason of any subdivision or consolidation of shares of stock of any class, the payment of any dividend, any increase or decrease in
the number of shares of stock of any class or any dissolution, liquidation, merger or consolidation of the Company or any other corporation. Except as expressly provided in the Plan, no issuance by the Company of shares of stock of any class, or
securities convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number of Shares subject to an Incentive Award or the exercise price of any Option, Tandem SAR or
Stand-Alone SAR. 
 13. Rights as a Stockholder 
 No person shall have any rights as a stockholder with respect to any Shares covered by or relating to any Incentive Award granted pursuant to this Plan until the date of the issuance of a stock certificate with respect to such shares.
Except as otherwise expressly provided in Section 12 hereof, no adjustment to any Incentive Award shall be made for dividends or other rights for which the record date occurs prior to the date such stock certificate is issued. 
 14. No Special Employment Rights; No Right to Incentive Award; Sale of a Division or Affiliate 
 (a) Nothing contained in the Plan or any Incentive Award shall confer upon any Participant any right with respect to the continuation of his employment
by the Company or interfere in any way with the right of the Company, subject to the terms of any separate employment or other agreement to the contrary, at any time to terminate such employment or to increase or decrease the compensation of the
Participant from the rate in existence at the time of the grant of an Incentive Award. 
 (b) No person shall have any claim or right to
receive an Incentive Award hereunder. The Committee’s granting of an Incentive Award to a Participant at any time shall neither require the Committee to grant an Incentive Award to such Participant or any other Participant or other person at
any time nor preclude the Committee from making subsequent grants to such Participant or any other Participant or other person. 
 (c) For
all purposes of this Plan, the employment of a Participant with the Company shall be deemed to have terminated without Cause upon a sale or other disposition by Kindred, directly or indirectly, of an Affiliate or any division or business unit of the
Company to which such Participant is allocated by the Committee, unless the Committee, in its sole discretion, determines otherwise. 
 15. Securities
Matters 
 (a) The Company shall be under no obligation to effect the registration pursuant to the Securities Act of any Shares to be
issued hereunder or to effect similar compliance under any state laws. Notwithstanding anything herein to the contrary, the Company shall not be obligated to cause to be issued or delivered any certificates evidencing Shares pursuant to the Plan
unless and until the Company is advised by its counsel that the issuance and delivery of such certificates is in compliance with all applicable laws, regulations of governmental authority and the requirements of any securities exchange on which
Shares are traded. The Committee may require, as a condition of the issuance and delivery of certificates evidencing Shares pursuant to the terms hereof, that the recipient of such shares make such covenants, agreements and representations, and that
such certificates bear such legends, as the Committee, in its sole discretion, deems necessary or desirable. 
 (b) The exercise of any
Option (including any Tandem SAR related thereto) or Stand-Alone SAR granted hereunder shall only be effective at such time as counsel to the Company shall have determined that the issuance and delivery of Shares pursuant to such exercise is in
compliance with all applicable laws, regulations of governmental authority and the requirements of any securities exchange on which Shares are traded. The Company may, in its sole discretion, defer the effectiveness of any exercise of an Option
(including any Tandem SAR related thereto) or Stand-Alone SAR granted hereunder in order to allow the issuance of Shares pursuant thereto to be made pursuant to registration or an exemption from registration or other methods for compliance available
under federal 

  

 13 

 
or state securities laws. The Company shall inform the Participant in writing of its decision to defer the effectiveness of the exercise of an Option, Tandem
SAR or Stand-Alone SAR granted hereunder. During the period that the effectiveness of the exercise of an Option, Tandem SAR or Stand-Alone SAR has been deferred, the Participant may, by written notice, withdraw such exercise and obtain the refund of
any amount paid with respect thereto. 
 16. Withholding Taxes 
 (a) Cash Remittance 
 Whenever Shares are to be issued upon the exercise of an Option, the vesting of a
Restricted Share, the payment of a Performance Unit or the grant of a Stock Bonus, the Company shall have the right to require the Participant to remit to the Company in cash an amount sufficient to satisfy federal, state and local withholding tax
requirements, if any, attributable to such exercise, vesting, payment or grant prior to the delivery of any certificate or certificates for such shares. In addition, upon the exercise of a Tandem SAR or Stand-Alone SAR or the payment of a
Performance Unit, the Company shall have the right to withhold from any cash payment required to be made pursuant thereto an amount sufficient to satisfy the federal, state and local withholding tax requirements, if any, attributable to such
exercise or payment. 
 (b) Stock Remittance 
 At the election of the Participant, when Shares are to be issued upon the exercise of an Option, the vesting of a Restricted Share, the payment of a Performance Unit or the grant of a Stock Bonus, the Participant may
tender to the Company a number of Shares previously held by such Participant for at least six months determined by such Participant, the Fair Market Value of which at the tender date the Company determines to be sufficient to satisfy the federal,
state and local withholding tax requirements, if any, attributable to such exercise, vesting, payment or grant and not greater than the Participant’s required federal, state and local tax obligations associated with such exercise, vesting,
payment or grant. Such election shall satisfy the Participant’s obligations under Paragraph 16(a) hereof, if any. 
 (c) Stock
Withholding 
 At the election of the Participant when Shares are to be issued upon the exercise of an Option, the vesting of a Restricted
Share, the payment of a Performance Unit or the grant of a Stock Bonus, the Company shall withhold a number of such shares determined by such Participant, the Fair Market Value of which at the exercise, vesting, payment or grant date the Company
determines to be sufficient to satisfy the federal, state and local withholding tax requirements, if any, attributable to such exercise, vesting, payment or grant and is not greater than the Participant’s required federal, state and local tax
obligations associated with such exercise or grant. Such election shall satisfy the Participant’s obligations under Paragraph 16(a) hereof, if any. 
 17. Amendment of the Plan 
 The Board of Directors may amend, alter or discontinue the Plan, but no amendment, alteration,
or discontinuation shall be made that would impair the rights of a Participant under an Award theretofore granted, without the Participant’s consent, or that without the approval of the Company’s stockholders would: 
 (a) except as is provided in Section 12 of the Plan, increase the total number of Shares reserved for the purpose of the Plan; or 
 (b) reduce the exercise price for Options, Stand-Alone SARS and Tandem SARS by repricing or replacing such Awards. 
 The Committee may amend the terms of any Award therefore granted, prospectively or retroactively, but no such amendment shall impair the rights of any
Participant without his consent. Except as provided in Section 12, the 

  

 14 

 
Committee shall not have the authority to cancel any outstanding Option and issue a new Option in its place with a lower exercise price; provided, however,
that this sentence shall not prohibit an exchange offer whereby the Company provides certain Participants with an election to cancel an outstanding Option and receive a grant of a new Option at a future date if such exchange offer only occurs with
stockholder approval. 
 18. No Obligation to Exercise 
 The grant to a Participant of an Option, Tandem SAR or Stand-Alone SAR, shall impose no obligation upon such Participant to exercise such Option, Tandem SAR or Stand-Alone SAR. 
 19. Transfers Upon Death 
 Upon the death of a
Participant, outstanding Incentive Awards granted to such Participant may be exercised or paid only by the executors or administrators of the Participant’s estate or by any person or persons who shall have acquired such right to exercise by
will or by the laws of descent and distribution. No transfer by will or the laws of descent and distribution of any Incentive Award, or the right to exercise any Incentive Award, shall be effective to bind the Company unless the Committee shall have
been furnished with (a) written notice thereof and with a copy of the will and/or such evidence as the Committee may deem necessary to establish the validity of the transfer and (b) an agreement by the transferee to comply with all the
terms and conditions of the Incentive Award that are or would have been applicable to the Participant and to be bound by the acknowledgements made by the Participant in connection with the grant of the Incentive Award. 
 20. Expenses and Receipts 
 The expenses of the Plan
shall be paid by the Company. Any proceeds received by the Company in connection with any Incentive Award will be used for general corporate purposes. 
 21.
Failure to Comply 
 In addition to the remedies of the Company elsewhere provided for herein, failure by a Participant to comply with
any of the terms and conditions of the Plan or the agreement executed by such Participant evidencing an Incentive Award, unless such failure is remedied by such Participant within ten days after having been notified of such failure by the Committee,
shall be grounds for the cancellation and forfeiture of such Incentive Award, in whole or in part, as the Committee, in its absolute discretion, may determine. 
 22. Effective Date and Term of Plan 
 The Plan was initially adopted by the Board of Directors on February 12, 2002; no
grants may be made under the Plan after the tenth anniversary of such date. 
 23. Code Section 409A 
 The Company intends that the Plan and each Incentive Award granted hereunder shall comply with Section 409A of the Code and any regulations
thereunder and that the Plan shall be interpreted, operated and administered accordingly. Any reservation of rights by the Company (including, without limitation, the rights of the Committee under Section 12(b)(ii) hereof) affecting the timing
of payment of any Incentive Award subject to Section 409A of the Code will only be as broad as is permitted by Section 409A of the Code and any regulations thereunder. 
  

 15Settlement Agreement

 Exhibit 10.1 
 SETTLEMENT AGREEMENT 
 This SETTLEMENT AGREEMENT (the “Agreement”) is made and
entered into as of May 19, 2008, by and between Cambridge Heart, a Delaware corporation (“Cambridge Heart”), AFB Fund, LLC, a New Jersey limited liability company (“AFB”), Louis Blumberg, a resident of the
State of New York and the manager of AFB (“Louis Blumberg”), and Laurence Blumberg, a resident of the State of New York and a member of AFB (“Laurence Blumberg”). 
 RECITALS 
 WHEREAS, AFB has nominated
Louis Blumberg (the “AFB Nominee”) to serve as a member of Cambridge Heart’s board of directors (the “Board”); 
 WHEREAS, in connection with Cambridge Heart’s 2008 annual meeting of stockholders (the “2008 Annual Meeting”), AFB intends to solicit proxies from Cambridge Heart’s stockholders (the
“Solicitation”) to elect Louis Blumberg as a member of the Board in lieu of a nominee recommended by the Board; 
 WHEREAS,
AFB has submitted a stockholder proposal to be considered at the 2008 Annual Meeting and included in Cambridge Heart’s proxy statement pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), which proposal seeks stockholder approval of a recommendation to the Board that the Amended and Restated Certificate of Incorporation of Cambridge Heart (the “Certificate of Incorporation”) be amended to eliminate
those provisions of the Certificate of Incorporation that provide for a staggered Board of Directors and to impose four-year term limits upon director service on the Board of Directors (the “Stockholder Proposal”); 
 WHEREAS, the Board of Cambridge Heart has determined that it is in the best interests of Cambridge Heart and its stockholders to (1) increase the
size of the Board and to add Louis Blumberg to the Board, in order to avoid the expense and disruption of the Solicitation, and (2) to eliminate the provisions of the Certificate of Incorporation that provide for a staggered Board of Directors
as provided herein; and 
 WHEREAS, concurrently with the execution of this Agreement by Cambridge Heart and AFB and as a condition to
AFB’s execution of this Agreement, AFB and Robert Khederian (“Mr. Khederian”), acting individually and not in his capacity as Chairman of the Board of Cambridge Heart, have entered into an agreement (the “Voting
Agreement”) with respect to (1) the nomination by AFB and Mr. Khederian of an individual to be elected by the holders of Series A Convertible Preferred Stock (the “Series A Preferred”) to serve as a director of
Cambridge Heart, and (2) the election by Mr. Khederian, as the majority holder of Series A Preferred, of such individual. 

 NOW, THEREFORE, in consideration of the premises, the mutual covenants and agreements contained herein
and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 ARTICLE I 
 AGREEMENTS 
 Section 1.1. Board Composition Matters; Nominations at 2008 Stockholder Meeting. 
 (a) Cambridge
Heart shall as promptly as practicable, and in any event within five business days after the date hereof, take all action necessary (including the calling of a special meeting of the Board to approve such actions): 
 (i) to expand the size of the Board so as to create one new directorship on the Board in accordance with Article Eleventh of the Certificate of
Incorporation and Article 2 of its Amended and Restated By-Laws, and 
 (ii) to appoint the AFB Nominee as a Class II director to fill such
newly-created directorship. 
 (b) Effective upon the appointment of Louis Blumberg to the Board pursuant to Section 1.1(a) hereof, AFB
hereby irrevocably withdraws its nomination of the AFB Nominee. 
 Section 1.2. Amendment to Certificate of Incorporation; Board
Recommendation. 
 (a) Cambridge Heart shall submit a proposal to its stockholders at the 2009 annual meeting of stockholders (the
“2009 Annual Meeting”) to amend Sections 2, 4, 5, 8 and 10 of Article Eleventh, as well as any other section or sections the amendment of which is necessary in order to eliminate the staggered Board of Directors, of the Certificate
of Incorporation in order to eliminate the staggered Board of Directors (the “Charter Amendment”). The Board shall recommend in its proxy statement for the 2009 Annual Meeting that stockholders of Cambridge Heart vote to approve the
Charter Amendment and Cambridge Heart shall use commercially reasonable efforts to solicit proxies to be voted at the 2009 Annual Meeting in favor of the Charter Amendment. 
 (b) If the Charter Amendment is approved at the 2009 Annual Meeting by the requisite vote of the stockholders of Cambridge Heart, Cambridge Heart agrees
to use all reasonable efforts, including the adjournment of the 2009 Annual Meeting in order to allow for the filing of the Charter Amendment with the Delaware Secretary of State, to permit the election of all directors nominated for election at the
2009 Annual Meeting for terms commencing at the 2009 Annual Meeting and expiring at the 2010 annual meeting of stockholders and until their successors are elected and qualified. 
 (c) If the Charter Amendment is approved at the 2009 Annual Meeting by the requisite vote of the stockholders of Cambridge Heart, the Board shall take
all action 

 
necessary to amend Sections 2.3, 2.4, 2.5 and 2.6 of Article 2 and Section 6.3 of Article 6, as well as any other section or sections the amendment of
which is necessary in order to eliminate the staggered Board of Directors, of Cambridge Heart’s Amended and Restated By-laws to eliminate the staggered Board of Directors. 
 Section 1.3. Termination of Solicitation and Stockholder Proposal. 
 (a) From the date hereof through the completion of the 2008 Annual Meeting, none of AFB, Louis Blumberg, Laurence Blumberg or any of their Affiliates
will, directly or indirectly, (i) solicit proxies or consents for the voting of any voting or other securities of Cambridge Heart or otherwise become a “participant,” directly or indirectly, in any “solicitation” of
“proxies” or consents to vote, or become a “participant” in any “election contest” involving Cambridge Heart or Cambridge Heart’s securities (all terms used herein and defined in Regulation 14A under the Exchange
Act having the meanings assigned to them therein), (ii) seek to advise or influence any person with respect to the voting of any securities of Cambridge Heart, (iii) initiate, propose or otherwise “solicit” Cambridge Heart
stockholders for the approval of shareholder proposals, (iv) otherwise communicate with Cambridge Heart’s stockholders or others pursuant to Rule 14a-1(l)(2)(iv) under the Exchange Act, (v) otherwise engage in any course of conduct
with the purpose of causing stockholders of Cambridge Heart to vote contrary to the recommendation of the Board on any matter presented to Cambridge Heart’s stockholders for their vote or challenging the policies of Cambridge Heart or
(vi) otherwise act, directly or indirectly, alone or in concert with others, to seek to control or influence the management, the Board, policies or affairs of Cambridge Heart, other than through Louis Blumberg, in his capacity as a member of
the Board. For purposes of this Agreement, “Affiliate” means, with respect to any person, any other person or entity that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common
control with, such first person and any employees, officers, members and managers of AFB. 
 (b) AFB hereby irrevocably withdraws the
Stockholder Proposal and consents to the exclusion of the Stockholder Proposal from Cambridge Heart’s proxy statement for the 2008 Annual Meeting. 
 Section 1.4. Voting Agreement. Until the completion of the 2008 Annual Meeting, AFB, Louis Blumberg and Laurence Blumberg shall, and shall cause each of their Affiliates to cause all voting securities of
Cambridge Heart beneficially owned by each of them to be present at the 2008 Annual Meeting for the purpose of establishing a quorum and to be voted at the 2008 Annual Meeting (i) for the director nominees recommended by the Board,
(ii) for Proposals 2 and 3 set forth in Cambridge Heart’s preliminary proxy statement for the 2008 Annual Meeting filed with the Securities and Exchange Commission on May 5, 2008, and (iii) in accordance with the recommendation
of the Board on any proposals of any other stockholder of Cambridge Heart, including with regard to any nomination of one or more nominees for election as director in opposition to the nominees of the Board at any such meeting. No later than five
business days prior to the 2008 Annual Meeting, each of AFB, Louis Blumberg and Laurence Blumberg shall, and shall cause each of its Affiliates to, vote in accordance with this 

 
Section 1.4. AFB, Louis Blumberg and Laurence Blumberg shall not, and shall cause each of their Affiliates not to, revoke or change any vote in
connection with any such meeting of stockholders unless such revocation or change is required or permitted in accordance with the first sentence of this Section 1.4. 
 Section 1.5 Nomination and Election of Series A Director. AFB and Louis Blumberg hereby acknowledge and agree that the nomination by AFB and Mr. Khederian of an individual to be elected by the Series
A Preferred to serve as a director of Cambridge Heart pursuant to the Voting Agreement shall be subject to the reasonable approval of at least 50% of the members of the Board of Directors of Cambridge Heart (excluding Mr. Khederian and Louis
Blumberg). 
 Section 1.6 Release of Claims. 
 (a) AFB, Louis Blumberg and Laurence Blumberg hereby acknowledge and agree that this Agreement is intended to be a complete and final settlement of any and all causes of action or claims that any of them has had, now
has or may now have, whether known or unknown, against Cambridge Heart or any of the persons or entities specified below. AFB, Louis Blumberg and Laurence Blumberg hereby, on behalf of themselves and anyone else claiming by, through or under any of
them, hereby waives, releases, covenants not to sue and forever discharges Cambridge Heart and its successors and each and all of their present and former officers, directors, agents and attorneys (hereinafter “CAMH Releasees”), and
each and all of them of, from and with respect to any and all debts, demands, actions, causes of action, suits, covenants, contracts, agreements, promises, torts, damages, claims, demands and liabilities whatsoever of any name and nature, both in
law and in equity (hereinafter “Claims”) that AFB, Louis Blumberg and/or Laurence Blumberg now has, may now have or ever had against each or any of the CAMH Releasees by reason of any matter, cause or thing whatsoever from the
beginning of the world to the date hereof, including, but not limited to, any Claims that may exist under federal, state or local laws. 
 (b) Cambridge Heart hereby acknowledges and agrees that this Agreement is intended to be a complete and final settlement of any and all causes of action or claims that Cambridge Heart has had, now has or may now have, whether known or
unknown, against AFB, Louis Blumberg and Laurence Blumberg or any of the persons or entities specified below. Cambridge Heart hereby, on behalf of Cambridge Heart and anyone else claiming by, through or under Cambridge Heart, hereby waives,
releases, covenants not to sue and forever discharges AFB, Louis Blumberg and Laurence Blumberg, and their successors and each and all of their present and former officers, directors, agents and attorneys (hereinafter “AFB
Releasees”), and each and all of them of, from and with respect to any and all Claims that Cambridge Heart now has, may now have or ever had against each or any of the AFB Releasees by reason of any matter, cause or thing whatsoever from
the beginning of the world to the date hereof, including, but not limited to, any Claims that may exist under federal, state or local laws. 

 ARTICLE II 
 MISCELLANEOUS PROVISIONS 
 Section 2.1 Representations and Warranties. 
 (a) Each of the parties hereto represents and warrants to the other parties that: 
 (i) such party has all requisite authority and power to execute and deliver this Agreement and to consummate the transactions contemplated hereby;

 (ii) the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly and validly
authorized by all required action on the part of such party and no other proceedings on the part of such party are necessary to authorize the execution and delivery of this Agreement or to consummate the transactions contemplated hereby; 

(iii) the Agreement has been duly and validly executed and delivered by such party and constitutes the valid and binding obligation of such party
enforceable against such party in accordance with their respective terms, and 
 (iv) this Agreement will not result in a violation of any
terms or provisions of any agreements to which such person is a party or by which such party may otherwise be bound or of any law, rule, license, regulation, judgment, order or decree governing or affecting such party. 
 (b) The parties hereto acknowledge, warrant and represent that they have carefully read this Agreement, understand it, have consulted with and received
the advice of counsel regarding this Agreement, agree with its terms, are duly authorized to execute it and freely, voluntarily and knowingly execute it. 
 Section 2.2 General. 
 (a) This Agreement shall be binding upon and inure to the benefit of and
be enforceable by the parties hereto and the respective successors, personal representatives and assigns of the parties hereto. 
 (b) This
Agreement contains the entire agreement between the parties with respect to the subject matter hereof and thereof and supersedes all prior and contemplated arrangements and understandings with respect thereto. 
 (c) This Agreement may be signed in counterparts, each of which shall constitute an original and all of which together shall constitute one and the same
Agreement. 
 (d) All notices and other communications required or permitted hereunder shall be effective upon receipt and shall be in
writing and may be delivered in person, by telecopy, electronic mail, express delivery service or U.S. mail, in which event it may be mailed by first-class, certified or registered, postage prepaid, addressed to the party to be notified at the
respective addresses set forth below, or at such other addresses which may hereinafter be designated in writing: 
 If to Cambridge Heart

 Cambridge Heart, Inc. 
 100
Ames Pond Road 
 Tewksbury, MA 01876 
 Attention: Mr. Ali Haghighi-Mood 
 Fax No.: (978) 654-4501 

 with a copy to: 
 Nutter, McClennen & Fish LLP 
 World Trade Center West 
 155 Seaport Boulevard 
 Boston,
Massachusetts 02210 
 Attention: Michelle L. Basil 
 Fax No.: (617) 310-9477 
 If to AFB or Louis Blumberg: 
 AFB Fund, LLC 
 2050 Center Avenue

 Fort Lee, NJ 07024 
 Attention: Louis Blumberg 
 Fax No.: (201) 585-2373 
 with a copy to: 
 McCarter and English , LLP

 Four Gateway Center 
 100
Mulberry Street 
 Newark, New Jersey 07102-4056 
 Attention: David A. Ludgin 
 Fax .: (973) 297-3715 
 If to Laurence Blumberg: 
 145 E. 81st St. 
 Apt 8E 
 New York, NY 10028 
 (e) This Agreement and the legal relations hereunder between the parties hereto shall
be governed by and construed in accordance with the laws of the State of Delaware applicable to contracts made and performed therein, without giving effect to the principles of conflicts of law thereof. 

 (f) Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be
effective and valid, but if any provision of this Agreement is held to be invalid or unenforceable in any respect, such invalidity or unenforceability shall not render invalid or unenforceable any other provision of this Agreement. 
 (g) It is hereby agreed and acknowledged that it will be impossible to measure in money the damages that would be suffered if the parties fail to comply
with any of the obligations herein imposed on them and that in the event of any such failure, an aggrieved person will be irreparably damaged and will not have an adequate remedy at law. Any such person, therefore, shall be entitled to injunctive
relief, including specific performance, to enforce such obligations, without the posting of any bond, and, if any action should be brought in equity to enforce any of the provisions of this Agreement, none of the parties hereto shall raise the
defense that there is an adequate remedy at law. 
 (h) Each party hereto shall do and perform or cause to be done and performed all such
further acts and things and shall execute and deliver all such other agreements, certificates, instruments and documents as any other party hereto reasonably may request in order to carry out the intent and accomplish the purposes of this Agreement
and the consummation of the transactions contemplated hereby. 
 (i) Each of the parties hereto hereby irrevocably and unconditionally
consents to submit to the exclusive jurisdiction of the courts of the State of Delaware and of the United States of America, in each case located in the County of New Castle, for any action, proceeding or investigation in any court or before any
governmental authority arising out of or relating to this Agreement and the transactions contemplated hereby (and agrees not to commence any action, proceeding or investigation relating thereto except in such courts), and further agrees that service
of any process, summons, notice or document by registered mail to its respective address set forth in this Agreement shall be effective service of process for any action, proceeding or investigation brought against it in any such court. Each of the
parties hereto hereby irrevocably and unconditionally waives any objection to the laying of venue of any action, proceeding or investigation arising out of this Agreement or the transactions contemplated hereby in the courts of the State of Delaware
or the United States of America, in each case located in the County of New Castle, and hereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such action, proceeding or investigation brought
in any such court has been brought in an inconvenient forum. 
 [Remainder of page intentionally left blank.] 

 IN WITNESS WHEREOF, the parties hereto have executed and delivered this Agreement as of the day and year first written
above. 
  

			
	CAMBRIDGE HEART, INC.
		
	By:	 	 /s/Ali Haghighi-Mood

	Name:	 	Ali Haghighi-Mood
	Title:	 	President and Chief Executive Officer
	
	AFB FUND, LLC
		
	By:	 	 /s/ Louis Blumberg

	Name:	 	Louis Blumberg
	Title:	 	Manager
	
	 /s/ Louis Blumberg

	Louis Blumberg
	
	 /s/ Laurence Blumberg

	Laurence Blumberg

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00142-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00142-of-00352.parquet"}]]